Objective To investigate the application effect of nedaplatin combined with docetaxel in patients with non-small cell lung cancer(NSCLC)complicated with pulmonary tuberculosis.Method A total of 60 patients with NSCLC complicated with pulmonary tuberculosis were selected,and all of them received anti-tuberculosis treatment.They were divided into nedaplatin group(n=30,treated with nedaplatin+docetaxel)and the cisplatin group(n=30,treat-ed with cisplatin+docetaxel)according to different treatment methods.The clinical efficacy,inflammatory response indi-cators[interleukin-2(IL-2),interleukin-6(IL-6),interferon-γ(IFN-γ),C-reactive protein(CRP)],immune function indica-tors[CD4+/CD8+,helper T cell(Th)1/Th2]were compared between the two groups.Result The total effective rate of treatment in nedaplatin group was 73.33%,which was higher than 43.33%in cisplatin group,and the difference was statis-tically significant(P<0.05).After treatment,the levels of IL-2,IFN-γ in both groups were higher than those before treat-ment,while the levels of IL-6,CRP were lower than those before treatment,the levels of IL-2,IFN-γ in nedaplatin group were higher than those in cisplatin group,while the levels of IL-6,CRP were lower than those in cisplatin group,and the differences were statistically significant(P<0.05).After treatment,the CD4+/CD8+,Th1/Th2 in both groups were higher than those before treatment,the CD4+/CD8+,Th1/Th2 in nedaplatin group were higher than those in cisplatin group,and the differences were statistically significant(P<0.05).Conclusion The nedaplatin combined with docetaxel and anti-tu-berculosis regimen has good clinical efficacy in treating patients with NSCLC complicated with pulmonary tuberculosis.It can improve immune function and alleviate inflammatory reactions.